Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Artificial intelligence (AI)–augmented analysis of quantitative circulating tumor DNA (ctDNA) burden and longitudinal kinetics to identify prognostic risk stratification in metastatic clear cell renal cell carcinoma (mccRCC).

Eric Martin, Eun-mi Yu, Laura Meili Linville et al. Jun 01, 2026 pp. 4522-4522 10.1200/jco.2026.44.16_suppl.4522

4522 Background: The relevance of ctDNA burden and longitudinal kinetics in RCC remains poorly defined. We applied AI–base...

Role of gallium-68-labeled FAPI-PET imaging in oncology: Results of a study in 310 patients.

Emirhan Harbi, Hamza Ugur Bozbey, Refik Bilgin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15076

e15076 Background: Current oncological PET imaging approaches rely on metabolic targets, primarily 18...

Impact of diabetes mellitus on inpatient outcomes among hospitalized patients with multiple myeloma: A National Inpatient Sample analysis (2018–2020).

Eliza Aisha, Ruqiat Masooma, Amna Zaheer et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19540

e19540 Background: Diabetes mellitus (DM) is common in patients with multiple myeloma (MM). While DM is often perceived as...

Tinengotinib (TT-00420) in advanced/metastatic FGFR2-altered cholangiocarcinoma following prior chemotherapy and FGFR inhibitor treatment: Results from a phase II study (FIRST-08).

Jun Zhou, Jiajia Yuan, Lan Zhang et al. Jun 01, 2026 pp. 4133-4133 10.1200/jco.2026.44.16_suppl.4133

4133 Background: Subsequent treatment options for advanced cholangiocarcinoma (CCA) after failure of chemotherapy and FGFR...

Influence of onboard, tethered IL-12 on potency of the Tmod NOT gate and selectivity.

Jushen Liang, Sara Imboden, Sanam Shafaattalab et al. Jun 01, 2026 pp. 2562-2562 10.1200/jco.2026.44.16_suppl.2562

2562 Background: To realize the full therapeutic potential of engineered immune cells in solid tumors, high potency must b...

Evaluating the organizational benefits of remote symptom monitoring during injectable outpatient cancer treatment: The final analysis of the randomized OPTIMACURE trial.

Audrey Faveyrial, Bénédicte Clarisse, Roman Rouzier et al. Jun 01, 2026 pp. 1637-1637 10.1200/jco.2026.44.16_suppl.1637

1637 Background: Remote monitoring (RM) to assess whether patients are apt for cancer treatment is already used during sta...

Physician ownership and investment interests in oncology: A national analysis of open payments data (2018-2024).

Raghavee Neupane, Delia Margaret Friel, Luke Xiyu Zhao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23024

e23024 Background: Financial relationships between physicians and industry raise concerns about conflicts of interest. The...

Phase IIb randomized trial of FOLFIRINOX plus ibrilatazar (ABTL0812) versus placebo as first-line treatment in metastatic pancreatic cancer: An analysis from the PanC-ASAP study.

Davendra Sohal, Anup Kasi, Inmaculada Gallego et al. Jun 01, 2026 pp. 4218-4218 10.1200/jco.2026.44.16_suppl.4218

4218 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) has poor prognosis and limited first-line treatment o...

Tumor-of-origin prediction using methylation signals from plasma cell-free DNA (cfDNA): Real-world experience in Asia and the Middle East (AME).

Ankur Bahl, Nitesh Rohatgi, Nir Peled et al. Jun 01, 2026 pp. 3051-3051 10.1200/jco.2026.44.16_suppl.3051

3051 Background: Accurate identification of tumor tissue of origin (TOO) is essential for guiding treatment decisions in a...

Clinical impact of <i>MSH3</i> loss-of-function alterations in patients treated with immune checkpoint blockade across cancer types.

Emily Linda Alouani, Violaine Randrian, Andrew Elliott et al. Jun 01, 2026 pp. 10516-10516 10.1200/jco.2026.44.16_suppl.10516

10516 Background: MSH3 is an alternate mismatch repair protein specialized in the recognition of larger indels through its...

Long-term safety outcomes of pregnancy among young breast cancer survivors: Results from a prospective, multicenter cohort study.

Kimia Sorouri, Yue Zheng, Samuel M. Niman et al. Jun 01, 2026 pp. 632-632 10.1200/jco.2026.44.16_suppl.632

632 Background: Prospective data on the risk of breast cancer (BC) recurrence among young BC survivors who have a subseque...

Efficacy and patient-reported outcome of trophoblast cell surface antigen-2 antibody-drug conjugate in advanced non–small cell lung cancer: An individual patient data survival analysis and meta-analysis.

Mahnoor Sukaina, Haritha Gandicheruvu, Kamalpreet Singh Singh Walia et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20511

e20511 Background: Trop-2 ADCs have emerged as a novel therapeutic approach in NSCLC that is refractory to chemotherapy an...

Robot-assisted versus laparoscopic radical nephrectomy for renal tumors in adults: A systematic review and meta-analysis.

Arbab Khalid, Fahad Amin, Ammad Abid et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16503

e16503 Background: Minimally invasive radical nephrectomy is the standard treatment for renal tumor resection. While lapar...

Comparison by immunotherapy agent of real-world outcomes with chemoimmunotherapy in first-line extensive-stage small cell lung cancer.

Anthony Alfonso, Paresh Kumar, Brook Marie Lobsiger et al. Jun 01, 2026 pp. 8103-8103 10.1200/jco.2026.44.16_suppl.8103

8103 Background: Chemoimmunotherapy became the standard of care for extensive-stage small cell lung cancer (ES-SCLC) after...

Prevalence of high-risk human papillomavirus infection in allogeneic stem cell transplant recipients.

Katherine Klein, Jessica Tristan Foreman, Devesh Malgave et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18565

e18565 Background: Persistent infection with high-risk human papillomavirus (HR-HPV) is an important cause of malignancy,...

Survival outcomes in melanoma of unknown versus known primary receiving immunotherapy: A systemic review and meta-analysis.

Serena Yun-Chen Tsai, Elena B. Hawryluk, Hensin Tsao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21500

e21500 Background: Historically, patients with melanoma of unknown primary (MUP) had better survival than those wi...

Lymphoma histology as independent predictor of ICU mortality after adjustment for illness severity: A retrospective cohort study of 1,268 patients.

Prahlad Rao Kulkarni, Shankar Biswas, Elangovan Krishnan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19106

e19106 Background: Lymphomas comprise biologically heterogeneous malignancies ranging from aggressive to indolent subtypes...

A randomized phase II study of capmatinib plus osimertinib with or without ramucirumab in patients with <i>EGFR</i> -mutant, <i>MET</i> -amplified stage IV or recurrent no–small cell lung cancer (Lung-MAP Sub-Study S1900G).

Sarah B. Goldberg, Mary Weber Redman, David Ross Camidge et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps8677

TPS8677 Background: Patients (pts) with advanced EGFR -mutant non-small cell lung...

A phase III placebo controlled randomized controlled trial using combination therapy for treatment-related fatigue in patients with prostate cancer.

Sriram Yennu, Penny A. Stanton, Seungtaek Choi et al. Jun 01, 2026 pp. 12005-12005 10.1200/jco.2026.44.16_suppl.12005

12005 Background: To determine if the combination of exercise (EX) plus methylphenidate (MP) is superior to EX plus placeb...

Epidemiology and survival of melanoma in Jordan, 2013-2022: A registry-based study of trends and histologic patterns.

Sudi Maiteh, Laith Sorour, Abdallah Matouq et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21542

e21542 Background: Melanoma is an aggressive skin malignancy with increasing global incidence and wide geographic variatio...

Evaluating nuclear lamina-associated alterations as predictors of prostate cancer recurrence.

Carlo Francisco Lanza, Sin-Han Chen, Lin Zhen Chen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17119

e17119 Background: Prostate cancer exhibits marked disparities, and despite definitive treatment, some men with clinically...

Chronotherapy in metastatic non–small cell lung cancer: Clinical outcomes according to immune checkpoint inhibitor administration time during the day in patients treated with first-line chemoimmunotherapy.

Bahadır Köylü, Ibrahim Beyhan, Fatih Selçukbiricik et al. Jun 01, 2026 pp. 8575-8575 10.1200/jco.2026.44.16_suppl.8575

8575 Background: Although circadian rhythms are known to modulate immune cell function, the effect of immune checkpoint in...

An NCDB analysis on the demographic, treatment, and survival of small cell carcinoma with fusiform cells of the lungs.

Eugene Manu, Ruiyang Wang, Suraj Puvvadi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20137

e20137 Background: Small cell carcinoma with fusiform cells (SCC-FC), commonly originating in the lungs, is clinically cha...

Clinicopathology-based machine learning model for prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer.

Enver Ozkurt, Fatma Zehra Sari, Mehmet Baysan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12567

e12567 Background: Pathologic Complete Response (pCR) following neoadjuvant chemotherapy (NAC) is a surrogate for long-ter...

Implementation of a cancer-oriented geriatric assessment (COGA) clinic to promote age-friendly cancer care: A type III hybrid implementation–effectiveness method in community practice.

Ganesh Prasad Merugu, Mamtha Balla, Sonali Doshi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps1681

TPS1681 Background: Cancer incidence increases with age, and adults aged ≥65 years account for the majority of new cancer...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page